pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
363
stories
15d
STAT+: Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
stat
15d
STAT+: Federal regulators invite industry, researchers, and lobbyists to closed-door meetings on clinical AI
stat
15d
STAT+: Federal regulators invite industry, researchers, and lobbyists to closed-door meetings on clinical AI
stat
15d
Erica Schwartz confirmed as CDC director, filling nearly yearlong vacancy
stat
15d
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
biospace
15d
STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety
stat
15d
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
15d
Lilly climbs, Novo falls as obesity drug battle intensifies
biopharma dive
15d
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
15d
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
15d
STAT+: Moderna launches early trial of Ebola mRNA vaccine
stat
15d
Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
biospace
15d
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
15d
‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
fiercebiotech
15d
STAT+: Senate inquiry suggests Trump administration softened kratom and tobacco policies in quid pro quo
stat
15d
STAT+: Exemption of rare disease therapies in drug-pricing pilots would wipe out huge savings, analysis finds
stat
16d
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
16d
Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat
biospace
16d
Amgen culls early-stage obesity candidate, makes pipeline updates
endpoints
16d
Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy
biospace
16d
STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
stat
16d
STAT+: Three biotechs with three news updates
stat
16d
Novo vs. Lilly: Q2's cardiometabolic grudge match
endpoints
16d
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
biospace
16d
Amgen drops early-stage obesity drug, upping pressure on MariTide
fiercebiotech
16d
STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more
stat
16d
Trans federal employees sue over revoked health coverage
stat
16d
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
fiercebiotech
16d
STAT+: As Trump administration pushes court-ordered mental health care, a new report raises questions
stat
17d
Recon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca
raps
← prev
page 2 of 13
next →
